This image taken on October 23, 2023, exhibits Ozempic treatment packing containers, an injectable antidiabetic drug, in a pharmacy in Riedisheim, jap France. FILE PHOTO/Agence France-Presse
WASHINGTON — A category of diabetes drugs, which embody the best-selling drug Ozempic, are related to a lowered danger of sure obesity-related cancers, in accordance with a research launched Friday.
Printed within the journal JAMA, the research in contrast sufferers with Sort 2 diabetes who have been handled with insulin versus sufferers who got a category of drug often called GLP-1 agonists, like Ozempic, between 2005 and 2018.
The researchers discovered that the sufferers who obtained GLP-1 agonists had a considerably decrease danger of creating 10 out of 13 cancers studied, together with kidney, pancreatic, esophageal, ovarian, liver and colorectal most cancers.
READ: WHO warns in opposition to faux batches of Ozempic
Among the many cancers which noticed no important change in danger have been thyroid most cancers and breast most cancers in postmenopausal girls.
“Weight problems is well-known to be related to no less than 13 most cancers varieties,” research creator Rong Xu mentioned in an e-mail to AFP.
“Our research gives proof that GLP-1RAs maintain promise in breaking the hyperlink between weight problems and most cancers,” Xu mentioned.
READ: My life on Ozempic, the so-called weight-loss ‘miracle drug’
Among the many medicine studied have been semaglutide — commercially bought as Ozempic — in addition to liraglutide and others. Ozempic was authorized in the USA in 2017.
GLP-1 agonists have been round for about 20 years, however a brand new era of those medicine, amongst them Ozempic, has been popularized for his or her extra important weight reduction results.
Xu advised that the protecting advantages demonstrated within the research could encourage medical doctors to prescribe GLP-1 therapies for diabetes sufferers as a substitute of different medicines like insulin.
